Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTB43H
|
|||
| Drug Name |
BI 905677
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | LDL receptor related protein-6 (LRP-6) | Target Info | Antagonist | [2] |
| Low-density lipoprotein receptor-related protein 5 (LRP5) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Wnt signaling pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Wnt signaling pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Presenilin action in Notch and Wnt signaling | ||||
| Wnt signaling network | ||||
| Canonical Wnt signaling pathway | ||||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | ||||
| Regulation of FZD by ubiquitination | ||||
| WikiPathways | Wnt Signaling Pathway | |||
| Wnt Signaling Pathway and Pluripotency | ||||
| Wnt Signaling Pathway Netpath | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03604445) This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.